PubRank

Stephen A Spector

Author PubWeight™ 126.71‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy 2012 20.08
2 Lymphocyte subsets in healthy children from birth through 18 years of age: the Pediatric AIDS Clinical Trials Group P1009 study. J Allergy Clin Immunol 2003 5.43
3 Identification of a candidate therapeutic autophagy-inducing peptide. Nature 2013 3.76
4 Human bocavirus: prevalence and clinical spectrum at a children's hospital. Clin Infect Dis 2006 2.38
5 Progression to neuropsychological impairment in human immunodeficiency virus infection predicted by elevated cerebrospinal fluid levels of human immunodeficiency virus RNA. Arch Neurol 2002 2.28
6 Long-term effects of protease-inhibitor-based combination therapy on CD4 T-cell recovery in HIV-1-infected children and adolescents. Lancet 2003 2.04
7 Virologic and immunologic outcomes after 24 weeks in HIV type 1-infected adolescents receiving highly active antiretroviral therapy. J Infect Dis 2004 1.98
8 Long-term observation of adolescents initiating HAART therapy: three-year follow-up. AIDS Res Hum Retroviruses 2007 1.84
9 Perinatal HIV counseling and rapid testing in Tijuana, Baja California, Mexico: seroprevalence and correlates of HIV infection. J Acquir Immune Defic Syndr 2006 1.83
10 Vitamin D inhibits human immunodeficiency virus type 1 and Mycobacterium tuberculosis infection in macrophages through the induction of autophagy. PLoS Pathog 2012 1.69
11 Human immunodeficiency virus type-1 infection inhibits autophagy. AIDS 2008 1.65
12 Antiretroviral treatment of US children with perinatally acquired HIV infection: temporal changes in therapy between 1991 and 2009 and predictors of immunologic and virologic outcomes. J Acquir Immune Defic Syndr 2011 1.55
13 CYP2B6 genetic variants are associated with nevirapine pharmacokinetics and clinical response in HIV-1-infected children. AIDS 2007 1.53
14 Hormonally active vitamin D3 (1alpha,25-dihydroxycholecalciferol) triggers autophagy in human macrophages that inhibits HIV-1 infection. J Biol Chem 2011 1.48
15 Clinical outcomes after an unstructured treatment interruption in children and adolescents with perinatally acquired HIV infection. Pediatrics 2008 1.47
16 Decrease in hospitalization and mortality rates among children with perinatally acquired HIV type 1 infection receiving highly active antiretroviral therapy. Clin Infect Dis 2004 1.37
17 HIV prevalence during pregnancy in Tijuana, Baja California, Mexico. AIDS 2003 1.36
18 Efavirenz pharmacokinetics in HIV-1-infected children are associated with CYP2B6-G516T polymorphism. J Acquir Immune Defic Syndr 2007 1.32
19 Substance use in HIV-Infected women during pregnancy: self-report versus meconium analysis. AIDS Behav 2010 1.26
20 Myelomeningocele in an infant with intrauterine exposure to efavirenz. J Perinatol 2005 1.18
21 Intrapatient variability of efavirenz concentrations as a predictor of virologic response to antiretroviral therapy. Antimicrob Agents Chemother 2004 1.18
22 Prevalence of primary HIV-1 drug resistance among recently infected adolescents: a multicenter adolescent medicine trials network for HIV/AIDS interventions study. J Infect Dis 2006 1.16
23 Toll-like receptor 8 ligands activate a vitamin D mediated autophagic response that inhibits human immunodeficiency virus type 1. PLoS Pathog 2012 1.13
24 An MDR1-3435 variant is associated with higher plasma nelfinavir levels and more rapid virologic response in HIV-1 infected children. AIDS 2005 1.11
25 Relationship of plasma HIV-1 RNA dynamics to baseline factors and virological responses to highly active antiretroviral therapy in adolescents (aged 12-22 years) infected through high-risk behavior. J Infect Dis 2004 1.11
26 Directly observed therapy (DOT) for nonadherent HIV-infected youth: lessons learned, challenges ahead. AIDS Res Hum Retroviruses 2010 1.08
27 Human immunodeficiency virus type 1 subtype C Tat fails to induce intracellular calcium flux and induces reduced tumor necrosis factor production from monocytes. J Virol 2007 1.07
28 Genetic influence of CCR5, CCR2, and SDF1 variants on human immunodeficiency virus 1 (HIV-1)-related disease progression and neurological impairment, in children with symptomatic HIV-1 infection. J Infect Dis 2003 1.05
29 Associations of chemokine receptor polymorphisms With HIV-1 mother-to-child transmission in sub-Saharan Africa: possible modulation of genetic effects by antiretrovirals. J Acquir Immune Defic Syndr 2008 1.04
30 Autophagy is increased in postmortem brains of persons with HIV-1-associated encephalitis. J Infect Dis 2011 1.02
31 HIV type 1 gp120-induced expansion of myeloid derived suppressor cells is dependent on interleukin 6 and suppresses immunity. J Infect Dis 2013 1.02
32 Safety and immunogenicity of 2009 pandemic H1N1 influenza vaccination in perinatally HIV-1-infected children, adolescents, and young adults. J Infect Dis 2012 1.00
33 Impaired lymphoid chemokine-mediated migration due to a block on the chemokine receptor switch in human cytomegalovirus-infected dendritic cells. J Virol 2004 1.00
34 Population pharmacokinetics and pharmacodynamics of zidovudine in HIV-infected infants and children. J Clin Pharmacol 2003 1.00
35 Undiagnosed respiratory viruses in children. Pediatrics 2008 0.99
36 Human metapneumovirus associated with central nervous system infection in children. Pediatr Infect Dis J 2009 0.98
37 Pharmacokinetics, safety, and 48-week efficacy of oral raltegravir in HIV-1-infected children aged 2 through 18 years. Clin Infect Dis 2013 0.97
38 An age-dependent association of mannose-binding lectin-2 genetic variants on HIV-1-related disease in children. J Allergy Clin Immunol 2008 0.97
39 Endothelial damage from cytomegalovirus-specific host immune response can be prevented by targeted disruption of fractalkine-CX3CR1 interaction. Blood 2007 0.97
40 Phase I/II, open-label trial of safety and immunogenicity of meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine in human immunodeficiency virus-infected adolescents. Pediatr Infect Dis J 2010 0.97
41 Host genetic determinants of human immunodeficiency virus infection and disease progression in children. Pediatr Res 2009 0.96
42 Human cytomegalovirus-specific CD4+-T-cell cytokine response induces fractalkine in endothelial cells. J Virol 2004 0.96
43 Nevirapine exposure with WHO pediatric weight band dosing: enhanced therapeutic concentrations predicted based on extensive international pharmacokinetic experience. Antimicrob Agents Chemother 2012 0.95
44 Impact of pregnancy on abacavir pharmacokinetics. AIDS 2006 0.95
45 Immunologic function and virologic suppression among children with perinatally acquired HIV Infection on highly active antiretroviral therapy. Med Care 2005 0.95
46 Impact of nucleoside reverse transcriptase inhibitors on mitochondria in human immunodeficiency virus type 1-infected children receiving highly active antiretroviral therapy. Antimicrob Agents Chemother 2007 0.95
47 High T-cell response to human cytomegalovirus induces chemokine-mediated endothelial cell damage. Blood 2007 0.95
48 Production of interferon α by human immunodeficiency virus type 1 in human plasmacytoid dendritic cells is dependent on induction of autophagy. J Infect Dis 2012 0.95
49 Psychological factors, beliefs about medication, and adherence of youth with human immunodeficiency virus in a multisite directly observed therapy pilot study. J Adolesc Health 2010 0.95
50 The monocyte chemotactic protein-1 -2578G allele is associated with elevated MCP-1 concentrations in cerebrospinal fluid. J Neuroimmunol 2004 0.95
51 Predictors of highly active antiretroviral therapy utilization for behaviorally HIV-1-infected youth: impact of adult versus pediatric clinical care site. J Adolesc Health 2011 0.95
52 Persistence of human immunodeficiency virus (HIV) type 1 DNA in peripheral blood despite prolonged suppression of plasma HIV-1 RNA in children. J Infect Dis 2002 0.94
53 CCL2 increases X4-tropic HIV-1 entry into resting CD4+ T cells. J Biol Chem 2008 0.94
54 Conformity of pediatric/adolescent HIV clinics to the patient-centered medical home care model. AIDS Patient Care STDS 2013 0.94
55 Immunogenicity and safety of 1 vs 2 doses of quadrivalent meningococcal conjugate vaccine in youth infected with human immunodeficiency virus. J Pediatr 2012 0.92
56 Antiretroviral therapy does not block the secretion of the human immunodeficiency virus tat protein. Infect Disord Drug Targets 2012 0.92
57 HIV-1 gp120 modulates the immunological function and expression of accessory and co-stimulatory molecules of monocyte-derived dendritic cells. J Hematother Stem Cell Res 2002 0.92
58 Autophagy induction by vitamin D inhibits both Mycobacterium tuberculosis and human immunodeficiency virus type 1. Autophagy 2012 0.92
59 CCR2 polymorphisms affect neuropsychological impairment in HIV-1-infected adults. J Neuroimmunol 2004 0.92
60 The C terminus of HIV-1 Tat modulates the extent of CD178-mediated apoptosis of T cells. J Biol Chem 2005 0.92
61 Genetic polymorphisms in CX3CR1 predict HIV-1 disease progression in children independently of CD4+ lymphocyte count and HIV-1 RNA load. J Infect Dis 2005 0.91
62 Mother-to-child HIV transmission in a cohort of pregnant women diagnosed by rapid HIV testing at Tijuana General Hospital, Baja California, Mexico. J Int Assoc Physicians AIDS Care (Chic) 2010 0.89
63 Differential induction of rat neuronal excitotoxic cell death by human immunodeficiency virus type 1 clade B and C tat proteins. AIDS Res Hum Retroviruses 2010 0.89
64 Differential induction of interleukin-10 in monocytes by HIV-1 clade B and clade C Tat proteins. J Biol Chem 2010 0.89
65 Impact of nucleoside reverse transcriptase inhibitors on mitochondrial DNA and RNA in human skeletal muscle cells. Antimicrob Agents Chemother 2008 0.89
66 CD4+ lymphocyte-based immunologic outcomes of perinatally HIV-infected children during antiretroviral therapy interruption. J Acquir Immune Defic Syndr 2011 0.88
67 Genetic variants in the host restriction factor APOBEC3G are associated with HIV-1-related disease progression and central nervous system impairment in children. J Acquir Immune Defic Syndr 2013 0.87
68 Associations of proinflammatory cytokine levels with lipid profiles, growth, and body composition in HIV-infected children initiating or changing antiretroviral therapy. Pediatr Infect Dis J 2010 0.87
69 Detection of replication-competent human immunodeficiency virus type 1 (HIV-1) in cultures from patients with levels of HIV-1 RNA in plasma suppressed to less than 500 or 50 copies per milliliter. J Clin Microbiol 2002 0.87
70 Comparison of molecular tests for detection and quantification of cell-associated cytomegalovirus DNA. J Clin Microbiol 2003 0.86
71 Impact of MCP-1-2518-G allele on the HIV-1 disease of children in the United States. AIDS 2006 0.86
72 Longitudinal analysis of lymphocyte ratios and HIV-1 intracellular DNA levels in children. J Infect Dis 2004 0.85
73 HIV-1 clade B Tat, but not clade C Tat, increases X4 HIV-1 entry into resting but not activated CD4+ T cells. J Biol Chem 2009 0.85
74 Inhibition of human immunodeficiency virus type-1 through autophagy. Curr Opin Microbiol 2013 0.85
75 Prevalence of chemokine and chemokine receptor polymorphisms in seroprevalent children with symptomatic HIV-1 infection in the United States. J Acquir Immune Defic Syndr 2004 0.84
76 High proportions of regulatory B and T cells are associated with decreased cellular responses to pH1N1 influenza vaccine in HIV-infected children and youth (IMPAACT P1088). Hum Vaccin Immunother 2013 0.84
77 Safety and immunogenicity of quadrivalent meningococcal conjugate vaccine in 2- to 10-year-old human immunodeficiency virus-infected children. Pediatr Infect Dis J 2012 0.84
78 Migration and risk factors for HIV acquisition in pregnant women in Baja California, Mexico. MedGenMed 2005 0.83
79 Incidence of and risk factors for community acquired pneumonia in US HIV-infected children, 2000-2005. AIDS 2011 0.82
80 Associations of Genetically Determined Continental Ancestry With CD4+ Count and Plasma HIV-1 RNA Beyond Self-Reported Race and Ethnicity. J Acquir Immune Defic Syndr 2016 0.82
81 Vitamin D-related host genetic variants alter HIV disease progression in children. Pediatr Infect Dis J 2013 0.81
82 Trends in hospitalizations among children and young adults with perinatally acquired HIV. Pediatr Infect Dis J 2014 0.81
83 HLA alleles are associated with altered risk for disease progression and central nervous system impairment of HIV-infected children. J Acquir Immune Defic Syndr 2011 0.80
84 The influence of HLA on HIV-associated neurocognitive impairment in Anhui, China. PLoS One 2012 0.80
85 Association of CD4+ T-lymphocyte counts and new thymic emigrants in HIV-infected children during successful highly active antiretroviral therapy. J Allergy Clin Immunol 2006 0.80
86 Parallel rapid HIV testing in pregnant women at Tijuana General Hospital, Baja California, Mexico. AIDS Res Hum Retroviruses 2012 0.79
87 Efavirenz liquid formulation in human immunodeficiency virus-infected children. Pediatr Infect Dis J 2002 0.79
88 Infant peripheral blood repetitive element hypomethylation associated with antiretroviral therapy in utero. Epigenetics 2015 0.79
89 Lack of protective effects of interleukin-4 -589-C/T polymorphism against HIV-1-related disease progression and central nervous system impairment, in children. J Infect Dis 2004 0.79
90 CYP2C19 genetic variants affect nelfinavir pharmacokinetics and virologic response in HIV-1-infected children receiving highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2010 0.78
91 Effect of Host Genetic Variation on the Pharmacokinetics and Clinical Response of Non-nucleoside Reverse Transcriptase Inhibitors. Futur HIV Ther 2008 0.77
92 Vitamin D earns more than a passing grade. J Infect Dis 2009 0.77
93 Associations of host genetic variants on CD4⁺ lymphocyte count and plasma HIV-1 RNA in antiretroviral naïve children. Pediatr Infect Dis J 2014 0.77
94 CYP2B6 genotype-directed dosing is required for optimal efavirenz exposure in children 3-36 months with HIV infection. AIDS 2017 0.76
95 Vitamin D attenuates nucleoside reverse transcriptase inhibitor induced human skeletal muscle mitochondria DNA depletion. AIDS 2013 0.76
96 Single high-dose vitamin D at birth corrects vitamin D deficiency in infants in Mexico. Int J Food Sci Nutr 2015 0.76
97 Pediatric treatment 2.0: ensuring a holistic response to caring for HIV-exposed and infected children. AIDS 2013 0.76
98 Raltegravir pharmacokinetics in neonates following maternal dosing. J Acquir Immune Defic Syndr 2014 0.76
99 Brief Report: APOL1 Renal Risk Variants Are Associated With Chronic Kidney Disease in Children and Youth With Perinatal HIV Infection. J Acquir Immune Defic Syndr 2016 0.75
100 Treatment of infants coinfected with HIV-1 and cytomegalovirus with combination antiretrovirals and ganciclovir. J Allergy Clin Immunol 2004 0.75
101 Associations of Low Vitamin D and Elevated Parathyroid Hormone Concentrations With Bone Mineral Density in Perinatally HIV-Infected Children. J Acquir Immune Defic Syndr 2017 0.75
102 Hospital and outpatient health services utilization among HIV-infected children in care 2000-2001. Med Care 2005 0.75
103 Clinical Outcomes and Hospitalizations among Children Perinatally Infected with HIV-1 in Baja California, Mexico. J Int Assoc Physicians AIDS Care (Chic) 2011 0.75
104 Protease inhibitors and decreased birth weight in HIV-infected pregnant women with impaired glucose tolerance. J Perinatol 2002 0.75
105 Comparison of the QuantiFERON TB Gold In-tube Assay With Tuberculin Skin Test for the Diagnosis of Latent Tuberculosis Infection Among HIV-infected and Uninfected Children. Pediatr Infect Dis J 2017 0.75
106 A Phase II/III Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines. Pediatr Infect Dis J 2017 0.75